Eikon Therapeutics今日宣布,其在研药物Eik1001的注册性II/III期临床试验——Teluride-008,已完成首位患者给药。这项研究专注于非小细胞肺癌(NSCLC)的治疗。
Eikon Therapeutics今日宣布,其在研药物Eik1001的注册性II/III期临床试验——Teluride-008,已完成首位患者给药。这项研究专注于非小细胞肺癌(NSCLC)的治疗。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.